Index
-
Market Cap
49.35M
Enterprise Value
-26.60M
Income
-73.89M
Sales
0.00M
Book/sh
1.65
Cash/sh
1.81
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
76
IPO
Nov 15, 2022
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.70
P/C
0.63
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
5.54
Current Ratio
5.54
Debt/Eq
0.03
LT Debt/Eq
0.01
Option/Short
No / Yes
EPS (ttm)
-1.83
EPS next Y
-1.52
EPS next Q
-0.42
EPS this Y
9.62%
EPS next Y
16.74%
EPS next 5Y
14.42%
EPS past 3/5Y
-12.47% -51.39%
Sales past 3/5Y
- -
EPS Y/Y TTM
14.08%
Sales Y/Y TTM
-
EPS Q/Q
11.74%
Sales Q/Q
-
Insider Own
22.47%
Insider Trans
-0.23%
Inst Own
44.82%
Inst Trans
2.94%
ROA
-63.96%
ROE
-74.12%
ROIC
-103.39%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-26.98%
SMA50
-34.84%
SMA200
-33.93%
Trades
Shs Outstand
42.91M
Shs Float
33.27M
52W High
3.56 -67.70%
52W Low
1.27 -9.45%
Volatility
17.51% 10.47%
ATR (14)
0.16
RSI (14)
27.27
Beta
1.99
Rel Volume
4.88
Avg Volume
265.22K
Volume
1,294,501
Perf Week
-20.69%
Perf Month
-34.66%
Perf Quarter
-47.73%
Perf Half Y
-34.29%
Perf YTD
-52.28%
Perf Year
-49.12%
Perf 3Y
-71.18%
Perf 5Y
-
Perf 10Y
-
Prev Close
1.40
Price
1.15
Change %
-17.86%
Analysts 10 incl. previous ratings
Rating Distribution 10 Buy · 0 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside May 05, 2025 Resumed P Piper Sandler
Overweight $6 +421.7% Jan 31, 2025 Initiated K KeyBanc Capital Markets
Overweight Sep 16, 2024 Upgrade L Ladenburg Thalmann
Neutral → Buy $16 +1,291.3% Apr 29, 2024 Downgrade L Ladenburg Thalmann
Buy → Neutral Mar 01, 2024 Initiated J JMP Securities
Mkt Outperform $14 +1,117.4% Dec 15, 2023 Resumed J Jefferies
Buy $17 → $12 +943.5% Oct 05, 2023 Initiated M Maxim Group
Buy Jun 02, 2023 Initiated O Oppenheimer
Outperform $25 +2,073.9% May 08, 2023 Initiated B BMO Capital Markets
Outperform $25 +2,073.9% Apr 27, 2023 Initiated L Ladenburg Thalmann
Buy $22 +1,813.0% Apr 20, 2023 Initiated H H.C. Wainwright
Buy $24 +1,987.0% Dec 12, 2022 Initiated P Piper Sandler
Overweight $25 +2,073.9% Dec 12, 2022 Initiated J Jefferies
Buy $17 +1,378.3% Dec 12, 2022 Initiated C Cowen
Outperform
Show Previous Ratings
Nov-16-26 04:05PM
Nov-06-26 08:00AM
Nov-04-26 04:30PM
(GlobeNewswire)
+4.19%
-9.77%
Oct-29-26 08:00AM
Oct-20-26 08:30AM
08:00AM
Loading…
Sep-02-26 08:00AM
Aug-31-26 08:30AM
Aug-12-26 04:05PM
Aug-05-26 08:30AM
Jul-21-26 04:30PM
May-21-26 07:30AM
May-15-26 04:00PM
(GlobeNewswire)
-7.81%
-6.78%
May-13-26 04:10PM
Apr-17-26 04:00PM
(GlobeNewswire)
+6.59%
+4.49%
Apr-15-26 04:05PM
07:21AM
Loading…
Mar-19-26 07:21AM
Mar-17-26 05:54PM
Mar-03-26 12:00PM
Feb-27-26 11:47AM
Feb-24-26 08:00AM
Feb-23-26 08:00AM
Feb-18-26 08:00AM
Jan-28-26 09:15AM
Jan-23-26 08:11AM
Jan-08-26 02:02PM
07:30AM
Jan-07-26 09:40AM
Jan-06-26 07:30AM
Dec-17-25 09:34AM
07:30AM
01:26AM
Loading…
Nov-29-25 01:26AM
Nov-13-25 04:10PM
(GlobeNewswire)
-9.21%
+8.21%
Nov-02-25 05:05AM
Oct-22-25 04:15PM
Oct-01-25 04:30PM
Aug-13-25 04:15PM
(GlobeNewswire)
+4.80%
+6.11%
May-17-25 12:30PM
May-14-25 04:10PM
May-05-25 09:55AM
Apr-28-25 12:23PM
Apr-25-25 08:00AM
Apr-24-25 11:00AM
Apr-23-25 01:41PM
01:28PM
Apr-22-25 11:19AM
Apr-14-25 09:35AM
Apr-07-25 04:05PM
Mar-28-25 12:00PM
09:35AM
Mar-27-25 05:44PM
Mar-19-25 08:00AM
Feb-06-25 08:16AM
04:54AM
Feb-05-25 03:45PM
08:00AM
Nov-13-24 07:00AM
Oct-17-24 08:00AM
Oct-16-24 04:00PM
Oct-12-24 08:28AM
Oct-11-24 08:00AM
Sep-14-24 03:10AM
Sep-10-24 08:00AM
Sep-09-24 07:00AM
Aug-15-24 09:40AM
Aug-13-24 08:00AM
Jun-21-24 09:40AM
Jun-05-24 09:40AM
May-29-24 08:00AM
May-28-24 09:47AM
May-20-24 09:40AM
May-14-24 01:54PM
08:00AM
May-10-24 08:50AM
Apr-29-24 07:08AM
Apr-24-24 04:01PM
(GlobeNewswire)
-3.26%
-10.84%
Apr-16-24 08:01PM
Apr-10-24 08:00AM
Apr-09-24 10:32AM
07:00AM
Mar-30-24 05:31AM
Mar-28-24 12:52PM
08:00AM
Mar-05-24 04:30PM
Mar-04-24 08:00AM
Feb-27-24 08:00AM
Feb-08-24 08:00AM
Feb-06-24 08:00AM
Jan-12-24 04:00PM
Jan-04-24 08:00AM
Jan-03-24 08:00AM
Nov-28-23 08:00AM
Nov-21-23 08:00AM
08:00AM
Nov-09-23 08:01AM
Oct-16-23 08:00AM
Sep-28-23 04:05PM
Sep-19-23 04:32PM
Sep-05-23 04:05PM
Aug-30-23 08:00AM
Aug-17-23 04:00PM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Peterson Katharine Chief Accounting Officer Nov 17 '26 Sale 1.45 107 155 17,926 Nov 19 04:43 PM Miller Mary Chief Legal Officer Nov 17 '26 Sale 1.45 193 280 81,009 Nov 19 04:41 PM Gamelin Erick Chief Development Officer Nov 17 '26 Sale 1.45 416 603 52,176 Nov 19 04:40 PM Devroe Eric Chief Operating Officer Nov 17 '26 Sale 1.45 628 911 145,721 Nov 19 04:39 PM Blume-Jensen Peter President and CEO Nov 17 '26 Sale 1.45 1,276 1,850 2,228,776 Nov 19 04:38 PM Blume-Jensen Peter President and CEO Nov 17 '26 Sale 1.45 504 731 385,355 Nov 19 04:38 PM Kristina Masson Officer Nov 17 '26 Proposed Sale 1.43 504 721 Nov 17 07:08 PM Peter Blume-Jensen Officer Nov 17 '26 Proposed Sale 1.43 1,276 1,825 Nov 17 07:06 PM Miller Mary Chief Legal Officer Oct 22 '26 Sale 1.84 513 944 81,202 Oct 26 04:03 PM Miller Mary Chief Legal Officer Oct 05 '26 Sale 1.99 294 585 81,715 Oct 07 05:02 PM Blume-Jensen Peter President and CEO Aug 25 '26 Sale 2.21 14,036 30,969 2,230,052 Aug 27 04:14 PM Peter Blume-Jensen Officer Aug 25 '26 Proposed Sale 2.18 14,036 30,598 Aug 25 08:40 PM Peterson Katharine Chief Accounting Officer Aug 18 '26 Sale 2.01 101 203 18,033 Aug 20 04:10 PM Miller Mary Chief Legal Officer Aug 18 '26 Sale 2.01 185 372 82,009 Aug 20 04:09 PM Gamelin Erick Chief Development Officer Aug 18 '26 Sale 2.01 400 804 52,592 Aug 20 04:08 PM Devroe Eric Chief Operating Officer Aug 18 '26 Sale 2.01 604 1,214 146,349 Aug 20 04:07 PM Blume-Jensen Peter President and CEO Aug 18 '26 Sale 2.01 1,229 2,470 2,244,088 Aug 20 04:07 PM Blume-Jensen Peter President and CEO Aug 18 '26 Sale 2.01 484 973 385,859 Aug 20 04:07 PM Levy Adam D. Chief Financial Officer Aug 04 '26 Sale 1.57 1,142 1,793 66,008 Aug 06 04:34 PM Miller Mary Chief Legal Officer Jul 21 '26 Sale 1.76 573 1,008 82,194 Jul 23 04:28 PM Blume-Jensen Peter President and CEO Jan 14 '26 Buy 1.68 49,000 82,124 2,095,771 Jan 16 04:02 PM Levy Adam D. Chief Financial Officer Jan 14 '26 Buy 1.70 8,832 14,999 20,983 Jan 16 04:01 PM Devroe Eric Chief Operating Officer Jan 13 '26 Buy 1.72 10,000 17,218 75,308 Jan 15 04:38 PM
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Ph.D. Dr. Peter Blume-Jensen M.D.
Ph.D. Ms. Kristina Masson M.B.A.
Chief Operating Officer Dr. Eric J. Devroe Ph.D.
Ph.D. Dr. Adam D. Levy M.B.A.
Vice President of Finance & Accounting Ms. Katharine Peterson CPA